Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial

Dai Maruyama, Hideki Goto, Takahiro Kumode, Keiko Aizawa, Noriko Fukuhara, Jason R Westin, Won Seog Kim, Chiemi Mori, Tatsuki Imaizumi, Koji Kato · 2026

Read Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial by Dai Maruyama, Hideki Goto, Takahiro Kumode, Keiko Aizawa, Noriko Fukuhara, Jason R Westin, Won Seog Kim, Chiemi Mori, Tatsuki Imaizumi, Koji Kato (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13401542.txt.

Description

Dai Maruyama and co-authors report a 2026 Japan subgroup analysis of the phase III SUNMO trial in relapsed or refractory large B-cell lymphoma. The trial tested subcutaneous mosunetuzumab, a T-cell-engaging bispecific antibody, plus polatuzumab vedotin, an antibody-drug conjugate, against a standard rituximab chemotherapy pairing.

In the full trial, 208 patients were randomized two to one, 138 to the new pairing and 70 to rituximab with gemcitabine and oxaliplatin. Sixteen patients came from Japan, nine on the new pairing and seven on the standard arm. Every Japanese patient on the new pairing responded, a 100 percent response rate, against about 57 percent on standard treatment. Progression-free survival was strongly prolonged as well. The authors frame the fixed-duration outpatient regimen as a new option that is easy to reach for this hard-to-treat lymphoma.

Catalog record

CREATORDai Maruyama, Hideki Goto, Takahiro Kumode, Keiko Aizawa, Noriko Fukuhara, Jason R Westin, Won Seog Kim, Chiemi Mori, Tatsuki Imaizumi, Koji Kato
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32706
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13401542

Browse the full library · About the Tower of Babel